Tamoxifen has been shown to reduce the risk of breast cancer recurrence by about 40-50% in patients with ER+ breast cancer. Raloxifene has been found to reduce the risk of invasive breast cancer by approximately 50% in postmenopausal women who are at high risk but does not appear to reduce the risk of non-invasive breast cancer types.
